Search results
Results from the WOW.Com Content Network
Serum estradiol remains at approximately 50 pg/mL for approximately four months post-injection (with a range of 10–92 pg/mL after several years of use), rising once MPA levels fall below 0.5 ng/mL. [211] Hot flashes are rare while MPA is found at significant blood levels in the body, and the vaginal lining remains moist and creased.
Medroxyprogesterone acetate [c] Provera [b] Progestin: Oral: 5–10mg/day Depo-Provera [b] Progestin: IM: 150mg every 3 months Depo-SubQ Provera 104: Progestin: SC: 104mg every 3 months Lynestrenol [c] Orgametril [b] Progestin: Oral: 5–10mg/day Finasteride [d] Propecia [b] 5αR inhibitor: Oral: 1mg/day Dutasteride [d] Avodart: 5αR inhibitor ...
In the past, medrogestone was used in the treatment of endometrial cancer and in some regimens for breast cancer, and, in men, for benign prostatic hyperplasia. It still finds use in the treatment of amenorrhea [ 14 ] and as the progestin component in certain forms of menopausal hormone therapy .
Compared to MPA, medroxyprogesterone is over two orders of magnitude less potent as a progestogen. [8] Medroxyprogesterone is also notable in that it is a minor metabolite of MPA. [9] In addition to its progestagenic activity, medroxyprogesterone is a weak antiandrogen in vitro on human androgen receptor. [10]
In 1981, in an experiment by Pierre Gagné, 48 males with long-standing histories of sexually deviant behaviour were given medroxyprogesterone acetate for as long as 12 months. Forty of those subjects were recorded as having diminished desires for deviant sexual behaviour, as well as less frequent sexual fantasies and greater control over ...
With 20 years of use, breast cancer incidence is about 1.5-fold higher with estrogen alone and about 2.5-fold higher with estrogen plus progestogen therapy relative to non-use. [151] The increase in breast cancer risk with estrogen and progestogen therapy was shown to be causal with conjugated estrogens plus medroxyprogesterone acetate in the ...
Major examples of progestins include the 17α-hydroxyprogesterone derivative medroxyprogesterone acetate and the 19-nortestosterone derivative norethisterone. The progestins are structural analogues of progesterone and have progestogenic activity similarly, but differ from progesterone in their pharmacological properties in various ways. [5]
Estradiol cypionate/medroxyprogesterone acetate (EC/MPA), sold under the brand name Cyclofem among others, is a form of combined injectable birth control. [2] It contains estradiol cypionate (EC), an estrogen, and medroxyprogesterone acetate (MPA), a progestin. [2] It is recommended for short-term use and is given once a month by injection into ...